-
1
-
-
33846457870
-
Cancer statistics, 2007
-
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43-66.
-
(2007)
CA Cancer J Clin
, vol.57
, Issue.1
, pp. 43-66
-
-
Jemal, A.1
Siegel, R.2
Ward, E.3
Murray, T.4
Xu, J.5
Thun, M.J.6
-
2
-
-
33847638137
-
Estimates of the cancer incidence and mortality in Europe in 2006
-
Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18(3):581-92.
-
(2007)
Ann Oncol
, vol.18
, Issue.3
, pp. 581-592
-
-
Ferlay, J.1
Autier, P.2
Boniol, M.3
Heanue, M.4
Colombet, M.5
Boyle, P.6
-
3
-
-
14944385553
-
Global cancer statistics, 2002
-
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.
-
(2005)
CA Cancer J Clin
, vol.55
, Issue.2
, pp. 74-108
-
-
Parkin, D.M.1
Bray, F.2
Ferlay, J.3
Pisani, P.4
-
4
-
-
85036727021
-
-
Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J, editors, Lyon: IARC Scientific Publications
-
Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J, editors. Cancer incidence in five continents. Lyon: IARC Scientific Publications; 1997. v. 7, N. 143.
-
(1997)
Cancer Incidence In Five Continents
, vol.7
, Issue.143
-
-
-
5
-
-
34547937751
-
Pancreatic cancer: Is this bleak landscape finally changing? Highlights from the 43rd ASCO Annual Meeting
-
Chicago, IL, 2007, (Online)
-
Saif MW. Pancreatic cancer: is this bleak landscape finally changing? Highlights from the 43rd ASCO Annual Meeting. Chicago, IL, 2007. JOP J Pancreas. (Online) 2007;8(4):365-73.
-
(2007)
JOP J Pancreas
, vol.8
, Issue.4
, pp. 365-373
-
-
Saif, M.W.1
-
6
-
-
8244254377
-
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
-
Burris HA, 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiani MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403-13.
-
(1997)
J Clin Oncol
, vol.15
, Issue.6
, pp. 2403-2413
-
-
Burris III, H.A.1
Moore, M.J.2
Andersen, J.3
Green, M.R.4
Rothenberg, M.L.5
Modiani, M.R.6
-
7
-
-
0029973785
-
A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma
-
Rothenberg ML, Abbruzzese JL, Moore M, Portenoy RK, Robertson JM, Wanebo HJ. A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer. 1996;78(3 Suppl):627-32.
-
(1996)
Cancer
, vol.78
, Issue.3 SUPPL.
, pp. 627-632
-
-
Rothenberg, M.L.1
Abbruzzese, J.L.2
Moore, M.3
Portenoy, R.K.4
Robertson, J.M.5
Wanebo, H.J.6
-
8
-
-
12244296736
-
Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: A randomized phase II trial
-
Scheithauer W, Schull B, Ulrich-Pur H, Schmid K, Kaderer M, Haider K, et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann Oncol. 2003;14(1):97-104.
-
(2003)
Ann Oncol
, vol.14
, Issue.1
, pp. 97-104
-
-
Scheithauer, W.1
Schull, B.2
Ulrich-Pur, H.3
Schmid, K.4
Kaderer, M.5
Haider, K.6
-
9
-
-
0022590834
-
CA 19-9 and pancreatic adenocarcinoma
-
Safi F, Beger HG, Bittner R, Buchler M, Krautzberger W. CA 19-9 and pancreatic adenocarcinoma. Cancer. 1986;57(4):779-83.
-
(1986)
Cancer
, vol.57
, Issue.4
, pp. 779-783
-
-
Safi, F.1
Beger, H.G.2
Bittner, R.3
Buchler, M.4
Krautzberger, W.5
-
10
-
-
0023851586
-
Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas
-
Glenn J, Steinberg WM, Kurtzman SH, Steinberg SM, Sindelar WF. Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol. 1988;6(3):462-8.
-
(1988)
J Clin Oncol
, vol.6
, Issue.3
, pp. 462-468
-
-
Glenn, J.1
Steinberg, W.M.2
Kurtzman, S.H.3
Steinberg, S.M.4
Sindelar, W.F.5
-
11
-
-
0028267303
-
The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer
-
Lundin J, Roberts PJ, Kuusela P, Haglund C. The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. Br J Cancer. 1994;69(3):515-9.
-
(1994)
Br J Cancer
, vol.69
, Issue.3
, pp. 515-519
-
-
Lundin, J.1
Roberts, P.J.2
Kuusela, P.3
Haglund, C.4
-
12
-
-
0032076257
-
Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy
-
Katz A, Hanlon A, Lanciano R, Hoffman J, Coia L. Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy. Int J Radiat Oncol Biol Phys. 1998;41(2):393-6.
-
(1998)
Int J Radiat Oncol Biol Phys
, vol.41
, Issue.2
, pp. 393-396
-
-
Katz, A.1
Hanlon, A.2
Lanciano, R.3
Hoffman, J.4
Coia, L.5
-
13
-
-
33750552959
-
Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer
-
Boeck S, Stieber P, Holdenrieder S, Wilkowski R, Heinemann V. Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology. 2006;70(4):255-64.
-
(2006)
Oncology
, vol.70
, Issue.4
, pp. 255-264
-
-
Boeck, S.1
Stieber, P.2
Holdenrieder, S.3
Wilkowski, R.4
Heinemann, V.5
-
14
-
-
0030049697
-
Phase II study of gemcitabine in patients with advanced pancreatic cancer
-
Carmichael J, Fink U, Russell RC, Spittle MF, Harris AL, Spiessi G, et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer. 1996;73(1):101-5.
-
(1996)
Br J Cancer
, vol.73
, Issue.1
, pp. 101-105
-
-
Carmichael, J.1
Fink, U.2
Russell, R.C.3
Spittle, M.F.4
Harris, A.L.5
Spiessi, G.6
-
15
-
-
0032780681
-
CA19-9: A pedictor of response in pancreatic cancer treated with gemcitabine and cisplatin
-
Heinemann V, Schermuly MM, Stieber P, Schulz L, Jüngst D, Wilkowkski R, et al. CA19-9: a pedictor of response in pancreatic cancer treated with gemcitabine and cisplatin. Anticancer Res. 1999;19(4A):2433-5.
-
(1999)
Anticancer Res
, vol.19
, Issue.4 A
, pp. 2433-2435
-
-
Heinemann, V.1
Schermuly, M.M.2
Stieber, P.3
Schulz, L.4
Jüngst, D.5
Wilkowkski, R.6
-
16
-
-
0034009704
-
Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer
-
Halm U, Schumann T, Schiefke I, Witzigmann H, Mossner J, Keim V. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer. 2000;82(5):1013-6.
-
(2000)
Br J Cancer
, vol.82
, Issue.5
, pp. 1013-1016
-
-
Halm, U.1
Schumann, T.2
Schiefke, I.3
Witzigmann, H.4
Mossner, J.5
Keim, V.6
-
17
-
-
0344837818
-
Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine
-
Saad ED, Machado MC, Wajsbrot D, Abramoff R, Hoff PM, Tabacof J, et al. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer. 2002;32(1):35-41.
-
(2002)
Int J Gastrointest Cancer
, vol.32
, Issue.1
, pp. 35-41
-
-
Saad, E.D.1
Machado, M.C.2
Wajsbrot, D.3
Abramoff, R.4
Hoff, P.M.5
Tabacof, J.6
-
18
-
-
20644464360
-
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial
-
Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23(15):3509-16.
-
(2005)
J Clin Oncol
, vol.23
, Issue.15
, pp. 3509-3516
-
-
Louvet, C.1
Labianca, R.2
Hammel, P.3
Lledo, G.4
Zampino, M.G.5
André, T.6
-
19
-
-
27144435114
-
CA19-9 as a prognostic factor in inoperable pancreatic cancer: The implication for clinical trials
-
Maisey NR, Norman AR, Hill A, Massey A, Oates J, Cunningham D. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer. 2005;93(7):740-3.
-
(2005)
Br J Cancer
, vol.93
, Issue.7
, pp. 740-743
-
-
Maisey, N.R.1
Norman, A.R.2
Hill, A.3
Massey, A.4
Oates, J.5
Cunningham, D.6
-
20
-
-
38549176328
-
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial
-
Hess V, Glimelius B, Grawe P, Dietrich D, Bodoky G, Ruhstaller T, et al. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol. 2008;9(2):132-8.
-
(2008)
Lancet Oncol
, vol.9
, Issue.2
, pp. 132-138
-
-
Hess, V.1
Glimelius, B.2
Grawe, P.3
Dietrich, D.4
Bodoky, G.5
Ruhstaller, T.6
-
21
-
-
33748445708
-
Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer
-
Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekas H, Rost A, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006;24(24):3946-52.
-
(2006)
J Clin Oncol
, vol.24
, Issue.24
, pp. 3946-3952
-
-
Heinemann, V.1
Quietzsch, D.2
Gieseler, F.3
Gonnermann, M.4
Schönekas, H.5
Rost, A.6
-
22
-
-
0036498787
-
Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer
-
Rocha Lima CM, Savarese D, Bruckner H, Dudek A, Eckardt J, Hainsworth J, et al. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol. 2002;20(5):1182-91.
-
(2002)
J Clin Oncol
, vol.20
, Issue.5
, pp. 1182-1191
-
-
Rocha Lima, C.M.1
Savarese, D.2
Bruckner, H.3
Dudek, A.4
Eckardt, J.5
Hainsworth, J.6
-
23
-
-
34249933404
-
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group
-
Moore MJ, Goldstein D, Hamm J, Hecht JR, Gallinger S, Au HJ, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960-6.
-
(2007)
J Clin Oncol
, vol.25
, Issue.15
, pp. 1960-1966
-
-
Moore, M.J.1
Goldstein, D.2
Hamm, J.3
Hecht, J.R.4
Gallinger, S.5
Au, H.J.6
-
24
-
-
0029613841
-
Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates
-
Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol. 1995;48(12):1503-10.
-
(1995)
J Clin Epidemiol
, vol.48
, Issue.12
, pp. 1503-1510
-
-
Peduzzi, P.1
Concato, J.2
Feinstein, A.R.3
Holford, T.R.4
-
25
-
-
0028063153
-
Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA19-9
-
Forsmark CE, Lambiase L, Vogel SB. Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA19-9. Pancreas. 1994;9(6):731-4.
-
(1994)
Pancreas
, vol.9
, Issue.6
, pp. 731-734
-
-
Forsmark, C.E.1
Lambiase, L.2
Vogel, S.B.3
-
26
-
-
0022640096
-
Serum CA 19-9 concentrations and computed tomography findings in patients with pancreatic carcinoma
-
Sakahara H, Endo K, Nakajima K, Nakashima T, Koizumi M, Ohta M, et al. Serum CA 19-9 concentrations and computed tomography findings in patients with pancreatic carcinoma. Cancer. 1986;57(7):1324-6.
-
(1986)
Cancer
, vol.57
, Issue.7
, pp. 1324-1326
-
-
Sakahara, H.1
Endo, K.2
Nakajima, K.3
Nakashima, T.4
Koizumi, M.5
Ohta, M.6
-
27
-
-
33745552215
-
Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma
-
Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C, Warshaw AL. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006;24(18):2897-902.
-
(2006)
J Clin Oncol
, vol.24
, Issue.18
, pp. 2897-2902
-
-
Ferrone, C.R.1
Finkelstein, D.M.2
Thayer, S.P.3
Muzikansky, A.4
Fernandez-Delcastillo, C.5
Warshaw, A.L.6
-
28
-
-
34247188535
-
Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer
-
Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol. 2007;25(18):2607-15.
-
(2007)
J Clin Oncol
, vol.25
, Issue.18
, pp. 2607-2615
-
-
Sultana, A.1
Smith, C.T.2
Cunningham, D.3
Starling, N.4
Neoptolemos, J.P.5
Ghaneh, P.6
-
29
-
-
4644327989
-
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate
-
Rocha Lima CM, Green MR, Rotche R, Mille WH Jr, Jeffrey GM, Cesar LA, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004;22(18):3776-83.
-
(2004)
J Clin Oncol
, vol.22
, Issue.18
, pp. 3776-3783
-
-
Rocha Lima, C.M.1
Green, M.R.2
Rotche, R.3
Mille Jr., W.H.4
Jeffrey, G.M.5
Cesar, L.A.6
-
30
-
-
33749071359
-
Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer
-
Abou-Alfa GK, Letourneau R, Harker G, Modiano M, Hurwitz H, Tchekmedjian NS, et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol. 2006;24(27):4441-7.
-
(2006)
J Clin Oncol
, vol.24
, Issue.27
, pp. 4441-4447
-
-
Abou-Alfa, G.K.1
Letourneau, R.2
Harker, G.3
Modiano, M.4
Hurwitz, H.5
Tchekmedjian, N.S.6
-
31
-
-
2342622567
-
Molecular-targeted agents in pancreatic cancer
-
Saad ED, Hoff PM. Molecular-targeted agents in pancreatic cancer. Cancer Control. 2004;11(1):32-8.
-
(2004)
Cancer Control
, vol.11
, Issue.1
, pp. 32-38
-
-
Saad, E.D.1
Hoff, P.M.2
-
32
-
-
35348915953
-
Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value?
-
Miksad RA, Schnipper L, Goldstein M. Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? J Clin Oncol. 2007;25(28):4506-7.
-
(2007)
J Clin Oncol
, vol.25
, Issue.28
, pp. 4506-4507
-
-
Miksad, R.A.1
Schnipper, L.2
Goldstein, M.3
-
33
-
-
0029951550
-
Tumor markers in patients with pancreatic carcinoma
-
Gattani AM, Mandeli J, Bruckner HW. Tumor markers in patients with pancreatic carcinoma. Cancer. 1996;78(1):57-62.
-
(1996)
Cancer
, vol.78
, Issue.1
, pp. 57-62
-
-
Gattani, A.M.1
Mandeli, J.2
Bruckner, H.W.3
|